Around the world has recently opened one after another Wuhan pneumonia (CCP virus) vaccine, however, after the outbreak of the new crown pneumonia variant pneumonia virus in the United Kingdom, market rumors that the vaccine is only for Covid-19 virus, the effect on the prevention and control of variant viruses is not so good, so including Pfizer, Moderna, BioNTech SE and other biotechnology companies involved in the development of vaccines, the stock fell hard one after another, including Moderna’s stock fell 8.99% on the 22nd alone, and once fell 11% during the day to close at $125.88, the biggest one-day drop since late November.
Moderna’s stock fell 8.99% on the 22nd, Pfizer also sank 1.74% to close at $36.74, while BioNTech SE, a German biotech company that has a partnership with Pfizer listed on Nasdaq, plunged 10% at one point during the session and closed down 5.5% at the end to close at $100.56.
Despite the poor trend of these biotech stocks on the 22nd, Moderna shares soared 543% this year, BioNTech SE also soared 180%, and only Pfizer sank 1%. Moderna and BioNTech SE are entirely benefited by vaccine R&D, while the impact of vaccines on Pfizer is only the tip of the iceberg.
For the global 22nd many biotech companies’ stocks hit hard phenomenon, the outside world speculates that it may be related to the new variant virus, and I am afraid that the stock market will face greater volatility.
Recent Comments